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The interactions of lipopolyamines, a class of structurally unique compounds currently being used as
transfection (lipofection) agents, with lipopolysaccharide (LPS) have been characterized. Our studies have
demonstrated that 1,3-di-oleoyloxy-2-(6-carboxyspermyl)-propylamide), available commercially as DOSPER,
binds to purified LPS with an affinity of about 1/10 that of polymyxin B. This essentially nontoxic compound
inhibits, in a dose-dependent manner, LPS-induced activation of the Limulus clotting cascade and the pro-
duction of tumor necrosis factor alpha (TNF-a) interleukin-6 (IL-6), and nitric oxide from LPS-stimulated
J774.A1 cells, a murine macrophage-like cell line. Cytokine inhibition is paralleled by decreased steady-state
levels of TNF-a and IL-6 mRNA and inhibits the nuclear translocation of nuclear factor kappa B. These
findings suggest that the lipopolyamine compound sequesters LPS, thereby blocking downstream cellular
activation events that lead to the production of proinflammatory mediators. Administration of DOSPER to
D-galactosamine-sensitized mice challenged either with LPS or with Escherichia coli organisms provided
significant protection against lethality both with and without antibiotic chemotherapy. Partial protection is
evident in LPS-challenged mice treated with DOSPER as late as 2 to 4 h following the endotoxin challenge. A
greater degree of protection is observed in E. coli-challenged animals receiving ceftazidime than in those
receiving imipenem, which is probably attributable to the higher levels of LPS released in vivo by the former
antibiotic. Potent antiendotoxic activity, low toxicity, and ease of synthesis render the lipopolyamines candidate
endotoxin-sequestering agents of potential significant therapeutic value.
It is now well recognized that endotoxins or lipopolysaccha-
rides (LPSs), which are structural components of the outer
membranes of gram-negative bacteria (40, 54), play a pivotal
role in the sepsis syndrome (44, 55). LPSs, which are released
from bacteria either by the body’s natural defense systems or
by antibiotics, are recognized by a variety of cell types in the
body, important among which is the monocyte/macrophage
(26). When these cells sense the presence of LPS, they respond
by producing numerous inflammatory mediators, including tu-
mor necrosis factor alpha (TNF-a) (5, 67), interleukin-1 b
(IL-1b) (23, 24), and IL-6 (24, 79). Other cells, such as the
endothelial cell, produce nitric oxide (38, 76). The production
of these mediators, under normal circumstances, is precisely
regulated and serves to orchestrate the body’s defense mech-
anisms. However, the unregulated overproduction of these
substances (52) leads to the clinical syndrome termed “septic
shock” (1, 7), which is characterized by fever, hypotension,
coagulopathy, hemodynamic derangement, tissue hypoperfu-
sion, and multiple-organ failure and which frequently culmi-
nates in death (13, 71). It is estimated that more than 300,000
cases of septic shock occur each year in the United States, and
at least half of these cases are caused by gram-negative organ-
isms (6). The therapy of septic shock, to date, has primarily
been supportive, and specific therapeutic modalities aimed at
controlling those pathophysiological mechanisms that lead to
the systemic inflammatory response which ultimately manifests
in shock are, unfortunately, as yet unavailable (13, 71).
One possible approach to addressing therapeutically the
problem of sepsis caused by gram-negative bacteria is to target
LPS itself by the use of an agent that would bind to and
sequester this potent microbial product, thereby preventing its
recognition by the monocyte/macrophage and other effector
cells. The strategy of sequestering LPS, historically, has been
addressed by the use of either polyclonal or monoclonal anti-
bodies raised against the structurally conserved regions of the
molecule (12, 60). However, clinical studies with polyclonal
antibodies (2, 82) have been difficult to interpret unequivocally
(36). Numerous clinical trials (11, 12, 73, 74, 81) designed to
test the therapeutic efficacy of monoclonal antibodies have, to
date, failed to establish that the use of such antibodies is of
clinical value.
Several LPS-binding proteins of nonimmunologic origin are
known to bind to endotoxin and neutralize the effects of en-
dotoxin and are currently being evaluated as candidate thera-
peutic agents. An endotoxin-binding protein (37, 58) obtained
from the horseshoe crab (Limulus polyphemus) and a protein
found in neutrophil granules, called bactericidal/permeability-
increasing protein (25, 34, 75), are being studied for their
potential application in the treatment of septic shock (27, 41).
Unfortunately, the production of these proteins for widespread
use as therapeutic agents is likely to prove costly and will
potentially have a significant effect upon health care costs for
the treatment of this disease.
The toxic center of the LPS molecule is a glycolipid moiety
called lipid A (54, 78) whose structure is highly conserved and
which is therefore very similar among gram-negative bacteria.
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For these reasons, lipid A presents a logical molecular target
for compounds designed to bind to LPS. The anionic and
amphiphilic nature of lipid A (56, 78) enables it to bind to
numerous substances which are positively charged and which
also possess an amphipathic character. We have, over the last
several years, characterized the interactions of LPS with a
number of classes of cationic amphipathic molecules including
proteins (15, 51, 65), peptides (14, 16, 18, 19), pharmaceutical
compounds (17, 21), and other synthetic polycationic amphi-
philes (20). Adducing the knowledge that we had gained from
these studies, we have identified a novel class of cationic am-
phiphiles, the lipopolyamines, and we report here on the char-
acterization of the endotoxin-binding and -neutralizing prop-
erties of some compounds representative of this class of
molecules.
MATERIALS AND METHODS
Reagents. The lipopolyamine compounds DOSPER [1,3-di-oleoyloxy-2-(6-
carboxyspermyl)-propylamide] and Transfectam (dioctadecylamidoglycylsper-
mine [DOGS]) were procured from Boehringer Mannheim (Indianapolis, Ind.)
and Promega Corporation (Madison, Wis.), respectively. DOSPER was supplied
as a clear, aqueous, sterile, buffered suspension bottled under argon at a con-
centration of 1 mg/ml, and DOGS was supplied as lyophilized material that was
reconstituted in ethanol just prior to use. Electrospray mass spectrometry was
performed with DOSPER and revealed the presence of both mono- and di-
oleoyl-substituted compounds. LipofectAMINE, a 3:1 (wt/wt) mixture of the
lipopolyamine 2,3-dioleoyloxy-N-[2(sperminecarboxamido)ethyl]-N,N-dimethyl-
1-propanaminiumtrifluoroacetate (DOSPA) and the neutral phospholipid
dioleoylphosphatidylethanolamine, was purchased from Life Technologies
(Gaithersburg, Md.). The chemical structures of these lipopolyamine compounds
are shown in Fig. 1. Smooth LPS from Escherichia coli O111:B4, Re LPS, and
diphosphoryl lipid A from E. coli K-12 D31m4 were from List Biologicals (Camp-
bell, Calif.). Smooth LPS from Salmonella abortus equi was obtained from Sigma
Chemical Co. (St. Louis, Mo.).
Spectroscopic characterization of the binding of lipopolyamines to LPS and
lipid A. The relative affinities of the interactions of the lipopolyamine compounds
with LPS and lipid A were determined by the highly sensitive dansylcadaverine
fluorescent probe method (16, 17). Briefly, the binding of the probe to LPS or
lipid A results in a blue shift and intensity enhancement in the emission spectrum
of dansylcadaverine. Compounds which bind to the lipid A moiety displace the
bound probe, resulting in concentration-dependent quenching of fluorescence.
The affinities of binding of the compounds were determined from 50% effective
doses (ED50) obtained by four-parameter logistic curve fitting of the displace-
ment curves (16, 17) and are expressed relative to that of polymyxin B.
LAL assay. A quantitative chromogenic version of the Limulus amebocyte
lysate (LAL) assay (QCL-1000) from Biowhittaker (Walkersville, Md.) was used.
A constant concentration of LPS (4 endotoxin units) was incubated with various
doses of the lipopolyamines (or polymyxin B as a control) at 37°C for 10 min in
pyrogen-free glass test tubes. A total of 50 ml of this mixture or of the LPS
standard was added to equal volumes of the LAL reagent and endotoxin-free
water, and the mixture was incubated for a further 10 min at 37°C in a sterile,
endotoxin-free, 96-well microtiter plate preequilibrated at 37°C, after which 100
ml of the chromogenic substrate solution was added to each well. The reaction
was terminated at 6 min by the addition of 25% acetic acid, and the absorbance
at 405 nm was read with a Dynatech MR 5000 plate reader. Free, bioactive LPS
in the LPS-lipopolyamine or LPS-polymyxin B mixtures was quantitated from
standard curves, which were linear from 0.1 to 2.0 endotoxin units. All samples,
standards, and blanks were assayed in quadruplicate.
Cytokine and nitric oxide assays. The ability of the lipopolyamine compounds
to inhibit the LPS-stimulated production of proinflammatory mediators was
tested with the murine macrophage-like cell line J774.A1 (American Tissue Type
Collection, Washington, D.C.). J774.A1 cells were seeded in a 96-well tissue
culture plate at 5 z 105 cells/well. Following overnight culture in RPMI 1640
supplemented with L-glutamine, 10% fetal bovine serum, penicillin, and strep-
tomycin, the cells were stimulated for 8 h with LPS alone (20 ng/ml) or LPS
preincubated with graded concentrations of DOSPER, DOGS, or polymyxin B
(control). Supernatants were harvested and assayed for TNF-a and IL-6 by
specific enzyme-linked immunosorbent assays (Genzyme, Cambridge, Mass.).
Nitric oxide was measured as nitrite with the Griess reagent (35).
TNF-a and IL-6 mRNA determination. J774.A1 cells were plated in 12-well
plates at a density of 5 z 106 cells/well. Following overnight culture, the cells were
stimulated as indicated above for 2 h. Total RNA was extracted with Trizol
(GIBCO BRL, Gaithersburg, Md.) as per the manufacturer’s instructions. Re-
verse transcription followed by 25 cycles of PCR was carried out with the
GeneAmp RNA PCR kit and the GeneAmp 9600 Thermal Controller (Perkin-
Elmer, Foster City, Calif.), according to the manufacturer’s instructions. Mouse
TNF-a, IL-6, and b-actin primers (Stratagene, La Jolla, Calif.) were used as
specified by the vendor. The PCR products were electrophoresed on a 1.6%
agarose gel, stained with 0.5 mg of ethidium bromide per ml, and photographed
under UV transillumination. Images were analyzed with ITTI 1.31 densitometry
software (Interactive Technologies International, St. Petersburg, Fla.).
NFkB nuclear translocation assay. J774.A1 cells (107) were stimulated with 10
ng of LPS per ml as described above for 45 min, and the nuclear factor kappa B
(NFkB) activity in nuclear protein extracts (22) was then determined by electro-
phoretic mobility shift assays (EMSAs) essentially as published earlier (46, 47).
Briefly, the supernatants were aspirated following stimulation and the cells were
washed once in ice-cold phosphate-buffered saline (PBS). The cells were then
lysed in hypotonic lysis buffer (10 mM HEPES [pH 7.9] containing 10 mM KCl,
1.5 mM MgCl2, and 0.5% Nonidet P-40) for 3 min, and the cellular contents were
harvested by scraping with a rubber policeman. The lysis buffer and all other
buffers described below contained the following protease inhibitors, which were
added after they were freshly prepared: 0.5 mM dithiothreitol, 0.5 mM phenyl-
methylsulfonyl fluoride, 1 mg of pepstatin A per ml, 10 mg each of aprotinin,
leupeptin, and type I-S soybean trypsin inhibitor per ml, and 0.1 mM sodium
orthovanadate (all from Sigma). All subsequent procedures were carried out at
4°C. The lysate was centrifuged at 3,000 rpm for 5 min, and the pellet was washed
twice with lysis buffer. Nuclear proteins were extracted from the pellet with 40 ml
of extraction buffer (20 mM HEPES [pH 7.9], 420 mM NaCl, 1.5 mM MgCl2, 0.2
mM EDTA, 25% glycerol) per sample. After vigorous mixing and incubation on
ice for 10 min, the suspension was centrifuged at 16,000 3 g for 5 min. The
FIG. 1. Chemical structures of the lipopolyamine compounds.
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supernatant (40 ml) containing the nuclear proteins was diluted with 60 ml of
dilution buffer (20 mM HEPES [pH 7.9], 50 mM KCl, 0.2 mM EDTA, 20%
glycerol), and the total protein content was determined by the Bradford dye
method.
Details of the NFkB-specific oligonucleotide and EMSA have been published
earlier (46, 47). The oligonucleotide contains two tandemly arranged NFkB sites
(underlined) derived from the human immunodeficiency virus type 1 enhancer
region (59-ATCAGGGACTTTCCGCT-GGGGACTTTCCG-39) (48, 53), and
its complementary strand with a 59 overhang was obtained from Genosys Inc.
The annealed duplex strands were filled in with [g-32P]dCTP (3,000 Ci/mmol; Du
Pont NEN) Klenow polymerase (Life Technologies), and a mixture of dATP,
dGTP and dTTP nucleotides and were purified by ethanol precipitation. One
microgram of nuclear protein extract was incubated for 30 min at 25°C with 3 mg
of poly(dI-dC) z poly(dI-dC) (Pharmacia), bovine serum albumin (3 mg/ml), and
;4 ng of labeled oligonucleotide (100,000 cpm) in a final volume of 30 ml of
EMSA buffer (10 mM Tris-HCl [pH 7.5] containing 200 mM NaCl, 5 mM EDTA,
5 mM b-mercaptoethanol, 20% glycerol, and 0.5% Nonidet P-40). Following the
binding reaction, 20 ml of the samples was electrophoresed at 15 V/cm through
a 6% nondenaturing polyacrylamide gel that was prepared in 45 mM Tris-borate
buffer (pH 8.0) containing 1 mM EDTA. The gels were then dried and processed
for autoradiography.
Mouse lethality experiments. Female, outbred, 9- to 11-week-old CF-1 mice
(Charles River, Wilmington, Mass.) weighing between 22 and 28 g were used in
the lethality experiments. Upon arrival, the mice were allowed to acclimatize for
a week prior to experimentation, were housed at five per cage in a controlled
environment at the American Association for Laboratory Animal Care-accred-
ited Kansas University Medical Center Animal Facility, and were fed mouse
chow ad libitum. The animals were sensitized to the lethal effects of LPS by
D-galactosamine (30–32). D-Galactosamine (800 mg/kg) and LPS (20 ng) were
given as a single injection intraperitoneally (i.p.) in freshly prepared PBS. In
some experiments, mice received i.p. graded doses of DOSPER diluted in PBS
immediately before the D-galactosamine–LPS challenge, while for other mice, a
fixed dose of DOSPER (or DOGS) was administered at various times before or
after the challenge. Lethality was determined at 24 h.
Other experiments were designed to investigate the possible protective effects
of DOSPER on antibiotic-induced in vivo release of LPS from viable gram-
negative bacteria (8, 9, 62). In the latter experiments, mice received graded doses
of E. coli suspension in PBS; the E. coli suspension had been harvested from
Trypticase soy broth at the mid-logarithmic phase and quantitated by turbidim-
etry at 650 nm (5 z 108 cfu/ml 5 A650 of 0.65). These mice received, at the same
time, by separate i.p. injection, 0.2 ml of either imipenem-cilastin (Merck Inc.,
Rahway, N.J.) or ceftazidime (Glaxo-Wellcome, Research Triangle Park, N.C.)
at concentrations of 2.5 and 5 mg/ml, respectively. DOSPER (40 mg/mouse,
0.2-ml volume) or saline (0.2 ml) was also injected i.p. at the same time. Lethality
was determined at 24 h following LPS challenge. The statistical significances of
the lethality data were analyzed by the Fisher one-tailed exact probability test.
RESULTS
The premise for the evaluation of molecules such as
DOSPER and DOGS as LPS-neutralizing agents is that these
compounds might possess those physical properties that would
enable them to bind to LPS, sequester it, and thereby inhibit
the manifestations of endotoxicity. We therefore first charac-
terized the interactions of these compounds with LPS using the
dansylcadaverine displacement method (16). Both lipopoly-
amine compounds displaced the bound fluorescent probe (Fig.
2). The ED50s (displacer concentrations corresponding to 50%
probe displacement) for DOSPER and DOGS are 6.1 and 3.5
mM, respectively. Polymyxin B, a peptide antibiotic well rec-
ognized for its ability to bind to the lipid A region of LPS (42)
and inhibit its toxicity (64), was used as a control substance in
these experiments, and its ED50 was determined to be 0.58
mM, consistent with values reported in the literature (16, 57).
DOSPER and DOGS also displace dansylcadaverine bound to
purified Re LPS and lipid A with comparable affinities (data
not shown), verifying that they interact with the lipid A region
of LPS. In this initial spectroscopic screening assay, Lipo-
fectAMINE also behaved indistinguishably from the other
lipopolyamines, with the ED50 of dansylcadaverine displace-
ment being 4.9 mM when corrected for the actual concentra-
tion of the active constituent (DOSPA) alone (data not
shown). However, this compound was excluded from further
characterization because of the presence of substantial
amounts of neutral phospholipid which may potentially con-
found the biological activity of the active constituent.
Having established that these molecules bind to LPS, it was
necessary to ascertain whether such binding would result in
inhibition of the biological activity of the endotoxin molecule.
DOSPER and DOGS inhibit LPS-induced activation of LAL
in a concentration-dependent manner (Fig. 3); the inhibitory
activities of both compounds are indistinguishable, each being
about 10-fold lower than that of polymyxin B. The lipopoly-
amines also inhibit nitrite, TNF-a, and IL-6 production in
J774.A1 cells stimulated with LPS (Fig. 4). That the inhibition
FIG. 2. Dansylcadaverine displacement activity. The dansylcadaverine con-
centration was 15 mM, and the LPS concentration was 20 mM. Experiments were
performed in 50 mM Tris-HCl (pH 7.4) with a Hitachi spectrofluorimeter at
25°C. Excitation and emission wavelengths were 340 and 515 nm, respectively.
Bandpasses were 5 nm for both monochromators. F, DOSPER; Œ, DOGS; ■,
polymyxin B. Displacement curves were fit by using the ALLFIT four-parameter
logistic curve fitting program (45) as described earlier (16, 17).
FIG. 3. Inhibition of the chromogenic LAL response to LPS by lipopoly-
amines. A total of 2.0 endotoxin units of E. coli O111:B4 reference LPS was
incubated with increasing concentrations of DOSPER, DOGS, or polymyxin B
(control). LPS was quantitated in the samples by extrapolation of standard curves
constructed for the reference LPS. Error bars represent standard deviations
determined for quadruplicate samples. F, DOSPER; Œ, DOGS; ■, polymyxin B.
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was not due to toxicity was verified by cell viability studies in
which no toxicity was detected for DOSPER even at concen-
trations of 100 mg/ml (Fig. 5). Furthermore, DOSPER does
not display hemolytic activity against human erythrocytes (Fig.
5). This is of particular significance since many cationic am-
phiphiles are markedly surface active, manifesting as potent
membrane-disruptive behavior. We further verified that the
inhibitory effect was specific for LPS, since the compounds did
not have any effect on the induction of TNF-a, IL-6, or NO in
supernatants of J774.A1 cells stimulated with phorbol myris-
tate acetate (data not shown). Because in all of these assays the
inhibition profiles of both compounds were very similar, we
elected to investigate DOSPER for a more complete profile of
its endotoxin-sequestering properties.
Since an LPS-sequestering agent would be expected to also
inhibit early cellular signaling events that precede mediator
production in LPS-responsive cells, we examined steady-state
TNF-a and IL-6 mRNA levels as well as the nuclear translo-
cation of NFkB, a well-known LPS-activated transcription fac-
tor (10, 59, 80). DOSPER completely inhibits IL-6 mRNA
expression at all concentrations tested, while its effect on
TNF-a mRNA is less pronounced (Fig. 6) but nevertheless
significant. This is probably because of the high basal levels of
mRNA in J774 cells, as has been observed by us and other
investigators. DOSPER also inhibits LPS-induced transloca-
tion of cytoplasmic NFkB into the nucleus (Fig. 6). The reduc-
tion in band intensity is comparable to that of resting, non-
stimulated cells (Fig. 6). The inhibition by DOSPER of NFkB
translocation, an early signaling event that precedes cytokine
mRNA transcription, substantiates the conclusion that the ob-
served LPS-antagonistic effects of the lipopolyamine com-
pound are, indeed, due to entrapment of free LPS in the form
of biologically inactive complexes.
Having established that DOSPER binds to LPS and inhibits
its activity in several in vitro assay systems, it was of importance
to examine if the compound would also antagonize LPS effects
in vivo, particularly given the susceptibility of DOSPER to
hydrolytic cleavage of its acyl chains (see Discussion). We
therefore evaluated the activity of the compound in the well-
established D-galactosamine-sensitized mouse model of endo-
FIG. 4. Inhibition of nitrite (A), TNF-a (B), and IL-6 (C) secretion in
J774.A1 cells stimulated with 20 ng of E. coli O111:B4 LPS per ml in the presence
of DOSPER (F), DOGS (Œ), or polymyxin B (■). Nitrite was determined by the
Griess assay, and the cytokines were quantitated by specific enzyme-linked im-
munosorbent assays. Datum points are mean values for quadruplicate samples.
The bar graphs on the left represent internal controls: RPMI alone (no stimu-
lation) or LPS alone (no inhibitors); error bars correspond to standard deviations
for six replicate samples.
FIG. 5. (A) Cytotoxicity of DOSPER. J774.A1 cells (1.5 z 106/well) were
incubated with DOSPER for 6 h. The supernatants were aspirated, 100 ml of
RPMI 1640 containing 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide was added to each well, and the plates were incubated for an additional 2 h.
The supernatants were discarded and the cells were solubilized in isopropanol.
The absorbance at 570 nm was read in a microplate reader. Datum points
represent means 6 standard deviations for eight replicate samples. (B) Hemo-
lytic activity of DOSPER. Fresh human saline-washed erythrocytes (type O Rh
positive; final hematocrit, 10%) were incubated with DOSPER in saline for 1 h
and were then centrifuged. Free hemoglobin in the supernatant was measured at
578 nm and is expressed as a percentage of the total hemoglobin released by
hypotonic lysis.
FIG. 6. (A) Cytokine mRNA (TNF-a or IL-6) in J774.A1 cells stimulated
with 20 mg of LPS per ml in the presence or absence of DOSPER or polymyxin
B. mRNAs were quantitated by reverse transcription-PCR. (B) NFkB activity in
J774.A1 cells. Cells were stimulated for 45 min with 10 ng of LPS per ml in the
presence of various amounts of DOSPER or polymyxin B. Resting cells and cells
treated with LPS alone (10 ng/ml) without inhibitors served as internal controls
(lanes 6 and 7 from the left, respectively). Nuclear protein extracts were sub-
jected to EMSA with a 32P-labeled NFkB oligonucleotide probe.
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toxic shock (30–32, 61–63). The data presented in Table 1
indicate that DOSPER affords protection against LPS-induced
lethality. The protection is dose dependent and, of note, is
evident even at supralethal LPS doses (e.g., five times the LPS
dose inducing 100% lethality). In the experiments described
above, DOSPER was administered premixed with LPS so as to
facilitate the formation of complexes. In order to determine if
DOSPER or DOGS would also bind in vivo to circulating LPS
and neutralize its toxicity, additional experiments were per-
formed. In those experiments the lipopolyamine was adminis-
tered separately at various times with respect to the time of
LPS challenge. The results of these experiments are summa-
rized in Table 2. It is clear that DOSPER or DOGS affords
nearly complete protection when administered simultaneously
with or 15 min before LPS administration (Table 2) but not
when the compound is given an hour prior to challenge, prob-
ably due to the rapid clearance of the compound. Particularly
noteworthy is the fact that partial protection is observed even
up to 4 h following LPS challenge, presumably a consequence
of the sequestration by DOSPER of circulatory forms of LPS
(bound to albumin [15], lipoproteins [28], or other serum pro-
teins [66]).
The efficacy of DOSPER was also evaluated in a variant of
the D-galactosamine mouse lethality model wherein LPS is
released in vivo by the action of antibiotics on gram-negative
bacteria (8, 9, 62). Live E. coli O111:B4 organisms were ad-
ministered along with cell wall-active antibiotics (imipenem or
ceftazidime) with or without DOSPER to D-galactosamine-
sensitized mice. Imipenem and ceftazidime have different
specificities for penicillin-binding proteins on the outer mem-
brane, and therefore, treatment with these drugs results in the
release of substantially different amounts of LPS, while they
exert very similar microbicidal potencies. Ceftazidime has been
shown to cause more LPS release, both in vitro (8) and in vivo
(9), than imipenem and therefore provides less protection than
imipenem in the D-galactosamine model. We reasoned that if
DOSPER were to function as a scavenger of circulating LPS, it
would enhance to a greater degree the protection obtained
with ceftazidime than that obtained with imipenem. Table 3
summarizes the results obtained in these experiments. As ex-
pected, when coadministered with ceftazidime, DOSPER
causes a distinct shift to the right in the lethality profiles (com-
bined results obtained with challenge doses of 105 and 106
organisms, 8 of 20 mice for mice receiving ceftazidime plus
DOSPER versus 18 of 20 mice for ceftazidime plus vehicle,
respectively; P , 0.05), signifying an increase in the 50% lethal
dose of more than an order of magnitude of the E. coli chal-
lenge dose; this effect is not apparent in the imipenem-treated
mice (9 of 19 versus 12 of 20, respectively; P . 0.1; Table 3).
Of interest, DOSPER also appears to afford some protection
in non-antibiotic-treated mice (4 of 10 mice for DOSPER-
treated mice versus 6 of 6 mice when mice were challenged
with 104 organisms), which is probably attributable to the se-
questration by the compound of LPS released spontaneously
by the action of plasma components such as complement (43,
72). DOSPER at concentrations of up to 75 mg/ml has no
detectable intrinsic antimicrobial effects on E. coli. Since poly-
cationic molecules have been known to permeabilize the outer
membranes of gram-negative bacteria (69, 70), we also evalu-
ated the possible potentiation effects of DOSPER on the mi-
crobicidal activities of several classes of antibiotics. DOSPER
neither enhances nor inhibits the antimicrobial effect of imi-
penem, ceftazidime, gentamicin, or rifampin (Fig. 7).
DISCUSSION
In the course of our continuing investigations aimed at elu-
cidating the structural determinants of endotoxin-sequestering
agents (14, 16, 17, 19, 21), we had earlier shown that com-
pounds with protonatable positive charges that are so disposed
that the distance between them is equivalent to the theoreti-
cally determined distance between the two anionic phosphates
on the lipid A moiety enable such molecules to bind well to
LPS. We had also shown that the presence of additional, ap-
propriately positioned hydrophobic functionalities serve to fur-
ther enhance binding affinity and stabilize the resultant com-
plexes, presumably due to favorable entropic contributions to
the free energy of interaction (17, 21). We had also noted in
these early, exploratory studies that the charge distribution
profiles in DNA and supramolecular assemblies of lipid A or
LPS are similar in certain respects; in both cases the negatively
charged phosphate groups occur at regular, periodic intervals
of defined distance and geometry (21). Furthermore, several
compounds that we observed to bind to LPS with high affinity
are known DNA binders. Our interest, therefore, turned to
DNA-binding substances, and we found that several of the
desirable structural features mentioned above are present in
certain members of a novel class of compounds, the lipopoly-
amines, of which DOSPER and DOGS are representative. The
lipopolyamines were originally developed and are currently
being used as DNA transfection (lipofection) reagents (3, 4,
29, 33, 39, 77).
TABLE 2. Effect of time of lipopolyamine administration on LPS-
induced lethality in D-galactosamine-sensitized mice
Groupa Time of lipopolyamineadministrationb
No. of dead mice/total no.
of mice tested
DOSPER
1 Control 11/12
2 21 h 10/12
3 215 min 3/12c
4 0 h 1/12c
5 11 h 7/11
6 12 h 7/12
7 14 h 7/12
DOGS
1 Control 10/10
2 21 h 6/10
3 0 h 0/10c
4 11 h 5/10
5 12 h 9/10
6 14 h 9/10
a Each D-galactosamine-sensitized mouse received 20 mg of S. abortus equi
LPS.
b DOGS or DOSPER dose, 40 mg/mouse. Control animals received 0.2 ml of
saline instead of lipopolyamine. 0 h, lipopolyamine was injected into the animals
i.p. immediately after LPS and D-galactosamine challenge.
c P , 0.005.
TABLE 1. Protective effect of DOSPER in D-galactosamine-
sensitized mice challenged with S. abortus equi LPS
LPS challenge dose
(ng/mouse)
No. of dead mice/total no. of mice receiving
the following DOSPER dose (mg/mouse):
0 10 40
0 0/5 0/5
10 9/10 1/10a 0/5a
20 5/5 2/5 0/5a
50 0/5
a P , 0.005.
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The studies described in this paper establish that lipopoly-
amine compounds such as DOSPER bind to LPS and attenu-
ate its toxic activities. The inhibition of early cellular activation
events, namely, NFkB translocation and cytokine mRNA tran-
scription, in conjunction with the inhibition of the more distal
response events of cytokine and NO production, strengthen
the premise that DOSPER acts via sequestration of LPS. The
binding affinity is relatively modest, about an order of magni-
tude lower than that of polymyxin B. This is to be anticipated
since although the intercationic distance of the spermine back-
bone is optimal for Coulombic interactions with the anionic
lipid A phosphate groups (21), the fatty acid substituents im-
pose potentially unfavorable steric properties, as has been
observed with spermidinyl derivatives bearing nonterminal
hydrophobic substituents (21). Nonetheless, complexes of
DOSPER or DOGS and LPS are sufficiently stable in the
presence of serum in in vitro conditions and, importantly, also
in vivo, so as to significantly inhibit LPS toxicity. Presumably,
the acyl substituents of DOSPER serve to stabilize the com-
plex, since other strongly LPS-binding dicationic ligands such
as pentamidine (17) (apparent Kd3 0.12 mM), which interact
with LPS predominantly via electrostatic interactions (21),
completely inhibit the Limulus gelation activity of LPS or lipid
A but only weakly block TNF-a, IL-1b, and IL-6 production in
cultured human peripheral blood mononuclear cells (18a).
The potential problem of low affinity is offset when the
ligand can be used at relatively high concentrations due to
mass action effects. In the clinical setting, however, this is not
always feasible because of toxicity and the ensuing low thera-
peutic index. DOSPER is relatively nontoxic. It is devoid of
detectable cytotoxic effects on J774.A1 cells up to 100 mg/ml,
the maximal concentration tested, and in some mice receiving
cumulative doses of 160 mg, no signs of acute toxicity were
observed (data not shown). The literature also contains reports
that DOSPER has been used in vivo as a transfection agent in
pregnant mice at a dose of 400 nmol (0.44 mg/mouse) without
any detectable toxicity in the dams or their progeny (68), and
U.S. Food and Drug Administration approval has been ob-
tained for the experimental use of at least one lipopolyamine
compound as a transfection agent in humans (49, 50). This
desirable property of low toxicity appears to be a common
attribute of several similar compounds and is likely a conse-
quence both of the susceptibility to hydrolytic cleavage of the
ester and amide linkages between the acyl substituents and the
spermine backbone and of the inertness of the products of
hydrolysis. The lability of the molecule, however, also implies
poor pharmacokinetic behavior, and the rapid elimination of
the circulatory pool of DOSPER would be consistent with the
lack of protection when it is administered 1 h prior to LPS
challenge in the D-galactosamine-sensitized mouse model.
It is to be noted that in mice sensitized with D-galactosamine,
death typically occurs at between 8 and 12 h (62). Of particular
interest, therefore, is the diminished lethality that is apparent
when DOSPER is administered even at 4 h following LPS
challenge (Table 2). In the in vivo LPS release mouse model,
a distinct enhancement of the protective effect of ceftazidime
against E. coli challenge is observed (Table 3). When taken
together with data previously obtained in this laboratory (8, 9),
this observation suggests that the effect is due to the elimina-
tion of free LPS released by the action of the antibiotic. The
TABLE 3. Protective effect of DOSPER in D-galactosamine-sensitized mice challenged with E. coli and cell wall-active antibiotics
E. coli challenge
(CFU/mouse)
No. of dead mice/total no. of mice treated with the followinga:
Saline Saline 1DOSPER
Imipenem 1
saline
Imipenem 1
DOSPER
Ceftazidime 1
saline
Ceftazidime 1
DOSPER
102 0/6
103 4/6 3/5 0/4 0/4
104 6/6 4/10b 0/10 1/10
105 9/10 6/10 2/9 8/10 2/10b
106 10/10 6/10 7/10 10/10 6/10b
107 5/5 9/10 7/10
a DOSPER (40 mg/mouse) and imipenem (0.5 mg/mouse) or ceftazidime (1.0 mg/mouse) were administered at the same time as the E. coli challenge. Results shown
are collated from two separate experiments.
b P , 0.005.
FIG. 7. Effect of DOSPER on antimicrobial activities of antibiotics. A total
of 104 CFU of E. coli was cultured in RPMI 1640 (without phenol red or serum)
containing graded concentrations of antibiotics with (——) or without (. . . . . .)
DOSPER (10 mg/ml) in a final volume of 200 ml. Bacterial density was estimated
by turbidimetry at 750 nm at 4 h. F, imipenem; Œ, gentamicin; ■, rifampin; ,
ceftazidime.
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kinetics of LPS release and its subsequent compartmentaliza-
tion in the peritoneal cavity, portal circulation, and extracellu-
lar fluid are as yet poorly understood in this model, and it
seems probable that the release and distribution of LPS are
relatively slow and sustained processes, unlike when purified
LPS is administered as a bolus dose. Given the anticipated
short half-life of DOSPER, it is possible that the partial pro-
tection observed in this model might be substantially enhanced
if the compound is administered as a continual infusion. This
remains to be tested.
These data, collectively, present a strong case for the feasi-
bility of sequestering LPS nonimmunologically by using small
molecules and emphasizes the potential therapeutic utility of
LPS-binding agents of low toxicity such as DOSPER. An
understanding of the structural determinants that ascribe en-
dotoxin-binding and -neutralizing activities in potential LPS-
binding ligands appears to be amenable to relatively straight-
forward considerations of the physicochemical aspects of the
LPS molecule and of its lipid A moiety. That a lead compound
could be identified only on the basis of its structure and then
could be evaluated rapidly provides a strong impetus for the
systematic and rational development of LPS-neutralizing
agents. DOSPER might serve as an excellent starting point, for
the simplicity and modularity of its structure lend it to the
design of a variety of analogs. A systematic evaluation of such
analogs would help incrementally refine the heuristics of de-
signing LPS-sequestering compounds.
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